The following is a reconciliation of goodwill by segment.


(in millions)	Medical Products & Therapies		Healthcare Systems & Technologies		Pharmaceuticals		Total
Balance as of December 31, 2025	$	1,265	$	3,087	$	577	$	4,929
Reallocation of goodwill	569		—		(569)		—



Currency translation	(29)		(6)		(8)		(43)
Balance as of June 30, 2026	$	1,805	$	3,081	$	—	$	4,886

As discussed in Note 16, in the second quarter of 2026, we implemented a new operating model to better align decision-making, cost structure, and execution across our businesses. Our business is now comprised of two reportable segments under this new operating model: Medical Products & Therapies and Healthcare Systems & Technologies. Previously, our reportable segments were comprised of three segments: Medical Products & Therapies, Healthcare Systems & Technologies, and Pharmaceuticals. Our former Pharmaceuticals segment is now reported in our Medical Products & Therapies segment. As a result of this segment change, we reallocated the goodwill from our previous Pharmaceuticals segment to a reporting unit within our Medical Products & Therapies segment. We also performed goodwill impairment assessments of both the legacy reporting units and new reporting units of our segments before and after the segment change and did not identify any goodwill impairments.

The following is a summary of our other intangible assets.


									Indefinite-lived intangible assets
(in millions)	Customer relationships		Developed technology, including patents		Trade names		Other amortized intangible assets		Trade names		In process Research and Development		Total
December 31, 2025
Gross other intangible assets	$	3,393	$	3,208	$	953	$	91	$	390	$	107	$	8,142
Accumulated amortization	(1,095)		(2,434)		(172)		(72)		—		—		(3,773)
Other intangible assets, net	$	2,298	774		781		19		390		107		4,369
June 30, 2026
Gross other intangible assets	$	3,391	$	3,189	$	953	$	91	$	390	$	107	$	8,121
Accumulated amortization	(1,201)		(2,568)		(207)		(72)		—		—		(4,048)
Other intangible assets, net	$	2,190	$	621	$	746	$	19	$	390	$	107	$	4,073

Intangible asset amortization expense was $145 million and $151 million for the three months ended June 30, 2026 and 2025, respectively, and $291 million and $306 million for the six months ended June 30, 2026 and 2025, respectively.